On July 18th, Gelunhui investor asked Yifang Biotechnology (688382.SH) on the investor interactive platform, "Do we need to provide additional materials for CDE drug review of the cancer drug Gercysib?" The company replied that the new drug application for Garsorasib is currently undergoing CDE review process.
益方生物(688382.SH)：Garsorasib新药上市申请正在CDE审评流程中
Yifang Biotechnology (688382.SH): The new drug Garsorasib is currently undergoing CDE review and approval for market launch.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.